Company

Translate Bio, Inc.

Headquarters: Lexington, MA, United States

Employees: 122

CEO: Mr. Ronald C. Renaud Jr., MBA

NASDAQ: TBIO

Market Cap

$514,992

USD as of Jan. 1, 2025

Market Cap History

Translate Bio, Inc. market capitalization over time

Evolution of Translate Bio, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Translate Bio, Inc.

Detailed Description

Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis. It is also developing MRT5500 for the treatment of SARS-CoV-2. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. has a collaboration and license agreement with Sanofi Pasteur Inc. The company was founded in 2011 and is headquartered in Lexington, Massachusetts. As of September 13, 2021, Translate Bio, Inc. operates as a subsidiary of Sanofi.

Top 1-year algo backtest: +327.04%

$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Financials

Last Financial Reports Date June 30, 2024
Revenue TTM $15.6 M
EBITDA $-28,074,000
Gross Profit TTM $7.5 M
Profit Margin -292.59%
Operating Margin -328.48%
Quarterly Revenue Growth -71.90%
Financial Reports & Statistics

Stocks & Indices

Translate Bio, Inc. has the following listings and related stock indices.


Stock: NASDAQ: TBIO wb_incandescent

Details

Headquarters:

29 Hartwell Avenue

Lexington, MA 02421

United States

Phone: 617 945 7361